Engage ~ Alterations in health/Alterations in Endocrine function: Hyperglycemia

Anatomy and Physiology of the Pancreas

  • The pancreas is an endocrine gland that is approximately six inches long and has a pear shape.

    • It lies transverse across the upper abdomen behind the stomach.

    • The wider end, referred to as the head, is located on the lower right side.

    • The pancreatic duct connects the pancreas to the duodenum.

    • The thinner end, known as the tail, is positioned on the left towards the spleen.

Functions of the Pancreas

  • The pancreas serves two main functions in the endocrine system:

    1. Endocrine Function

    • It secretes hormones such as insulin and glucagon.

    • Insulin: Secreted by beta cells in the islets of Langerhans to regulate blood glucose levels.

    • Glucagon: Released in response to low blood glucose levels to prevent hypoglycemia, promoting the release of glucose from stored glycogen.

    1. Exocrine Function

    • It secretes digestive enzymes such as amylase and lipase.

    • Exocrine Gland Definition: A gland that releases substances through a duct or other opening in the body.

Blood Glucose Regulation

  • Glucose: The primary source of fuel for the body and brain, requiring insulin to move across cell membranes into cells.

  • Insulin Resistance: Occurs when insulin receptors on target cells fail to accept insulin, leading to high blood sugar levels.

    • Insulin resistance can be due to various factors including a lack of insulin or reduced production capabilities of the pancreas.

Hyperglycemia

  • Definition: Blood glucose (BG) levels higher than the expected range.

    • Fasting Blood Glucose: Greater than 110 mg/dL.

    • Casual Blood Glucose: Greater than 200 mg/dL.

  • Types of Diabetes:

    • Type 1 Diabetes Mellitus (t1 DM): A condition marked by hyperglycemia due to the pancreas's inability to produce insulin.

    • Type 2 Diabetes Mellitus (t2 DM): Characterized by insulin resistance and eventual insulin deficiency.

Mechanisms of Glycemic Control

  • When cells cannot absorb glucose due to a lack of insulin, the liver releases glucagon stores:

    • Gluconeogenesis: The production of glucose from non-carbohydrate sources, such as proteins, lipids, pyruvate, or lactate.

    • Glycogenolysis: The breakdown of glycogen into glucose, mainly occurring in the liver and muscle cells.

    • Lipolysis: Breakdown of stored fatty acids to generate energy.

    • Proteolysis: Breakdown of protein into amino acids.

Hyperglycemic Hyperosmolar State (HHS)

  • Definition: A severe metabolic complication of hyperglycemia typically seen in t2 DM, characterized by excessive dehydration and elevated blood glucose levels:

    • Symptoms include severe dehydration, hypotension, altered mental status, and absence of ketosis.

    • Plasma Osmolarity: A measure of hydration status influenced by solutes such as sodium, glucose, and urea.

Risk Factors for Hyperglycemia

  • Modifiable Factors:

    • Lifestyle choices such as diet and physical activity.

    • Use of certain medications (e.g., steroids, diuretics).

    • Illness or infection, chronic stress, and inadequate sleep.

  • Non-Modifiable Factors:

    • Genetic predisposition to metabolic disorders.

    • Age, family history, and ethnic background impacting risk.

  • Glycemic Control & Financial Resources: Inadequate financial resources and social determinants affect the ability to manage hyperglycemia effectively, contributing to health disparities.

Comorbidities and Complications of Hyperglycemia

  • Comorbidities: Include autoimmune disorders, hyperlipidemia, gestational diabetes, polycystic ovary syndrome (PCOS), metabolic syndrome, and Cushing's syndrome.

  • Untreated Complications: Can lead to:

    • Permanent damage to blood vessels, nerves, tissues, and organs.

    • Conditions such as coronary artery disease, cerebrovascular disease, and retinopathy.

    • Increased occurrence of ketosis and diabetic ketoacidosis (DKA) which can lead to unconsciousness or death.

Manifestations of Hyperglycemia

  • Manifestations include:

    • Polydipsia: Excessive thirst.

    • Polyphagia: Excessive hunger.

    • Polyuria: Excessive urination.

  • Other symptoms can include dry mouth, blurred vision, weakness, headaches, and nausea.

    • DKA may present with fruity breath and Kussmaul respirations, which are deep, rapid breaths to compensate for metabolic acidosis caused by high ketone levels.

Diagnostic Tests for Hyperglycemia

  • Blood Glucose Testing: Recommended testing involves assessment of fasting, random, and postprandial (after meal) blood glucose levels.

    • Fasting blood glucose considered elevated if >106 mg/dL.

    • Random blood glucose >200 mg/dL indicates hyperglycemia.

    • Hemoglobin A1c (HbA1c): Reflects average blood glucose over 2-3 months.

    • HbA1c of 7% correlates with an average glucose of 170 mg/dL.

    • Diagnostic imaging such as CT, ultrasound, and MRI can be used to investigate other causes of hyperglycemia.

Nursing Process for Hyperglycemia Management

  • Assessment:

    • Measure blood glucose levels and assess for symptoms of dehydration and concentration in electrolytes.

    • Monitor vital signs and neurological status for any changes in cognition.

  • Analysis:

    • Identify causes contributing to hyperglycemia and prioritize treatment based on findings.

  • Planning:

    • Develop individualized treatment plans focusing on lifestyle changes, medication administration, and ongoing monitoring.

  • Implementation:

    • Initiate appropriate interventions, which might include medication adjustments for blood glucose management.

  • Evaluation:

    • Assess effectiveness of treatment through follow-up blood glucose levels and overall client health status.

Treatment and Therapy Options for Hyperglycemia

  • Management Strategies:

    • Lifestyle modifications with diet and exercise, potentially alongside oral hypoglycemic drugs or insulin therapy.

  • Medication Classes:

    • Sulfonylureas (e.g., glyburide): Increase insulin secretion.

    • Thiazolidinediones (e.g., pioglitazone): Reduce insulin resistance.

    • Metformin: Reduces hepatic glucose production and improves insulin sensitivity.

    • DPP-4 Inhibitors (e.g., sitagliptin): Modulate blood sugar by influencing incretin hormone levels.

    • SGLT2 Inhibitors (e.g., canagliflozin): Promote urinary glucose excretion.

  • Client Education:

    • Teach clients about blood glucose monitoring, medication adherence, dietary changes, and recognizing symptoms of hypo or hyperglycemia.

  • Collaborative Care:

    • Referral to specialists like endocrinologists and dietitians as needed for comprehensive management.